Medtronic, Inc. Wins U.S. Patent Case Against Gore Involving Stent Grafts
Published: Jun 27, 2012
The patent in question involved a method of making stent grafts, which are implantable medical devices used to treat aortic aneurysms. The judge determined that Medtronic's stent grafts did not infringe Gore's U.S. Patent No. 5,810,870.
"We're pleased with the court's decision," said Tony Semedo, vice president and general manager for the Endovascular Therapies at Medtronic, "which enables us to continue our focus on advancing the standard of care for the endovascular repair of aortic aneurysms. In that context, respect for intellectual property remains a core principle that we continuously and vigorously defend. "
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
Medtronic, Inc. ( www.medtronic.com ), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.